Source comparison
Quick Comparison Table
Type. Sermorelin is a GHRH analog (GRF 1-29). CJC-1295 without DAC is a modified GHRH analog (Mod GRF). CJC-1295 with DAC is a modified GHRH analog incorporating an albumin-binding complex. Amino acids. Sermorelin: 29 amino acids, identical to native GHRH 1-29
This comparison does not assign a generated winner or score.
- Type. Sermorelin is a GHRH analog (GRF 1-29). CJC-1295 without DAC is a modified GHRH analog (Mod GRF). CJC-1295 with DAC is a modified GHRH analog incorporating an albumin-binding complex.
- Amino acids. Sermorelin: 29 amino acids, identical to native GHRH 1-29 (~3,358 Da). CJC-1295 without DAC: 29 amino acids with 4 stabilizing substitutions (~3,368 Da). CJC-1295 with DAC: 30 amino acids with 4 substitutions plus the DAC lysine (~4,500 Da).
- Receptor target. All three bind the GHRH-R on pituitary somatotrophs.
- Half-life. Sermorelin: approximately 11 to 12 minutes. CJC-1295 without DAC: approximately 30 minutes. CJC-1295 with DAC: 5 to 8 days.
- GH release pattern. Sermorelin and CJC-1295 without DAC both produce pulsatile, brief GH release. CJC-1295 with DAC produces sustained, more continuous GH elevation.
- GH elevation magnitude. Sermorelin and CJC-1295 without DAC produce moderate, dose-dependent GH elevation. CJC-1295 with DAC produces 2- to 10-fold GH elevation lasting 6 or more days from a single injection.
- IGF-1 elevation. Sermorelin and CJC-1295 without DAC produce significant IGF-1 elevation with ongoing daily therapy. CJC-1295 with DAC produces 1.5- to 3-fold IGF-1 elevation sustained for 9 to 11 or more days.
- Dosing frequency. Sermorelin: daily (5 to 7 nights per week). CJC-1295 without DAC: 1 to 2 times daily. CJC-1295 with DAC: 1 to 2 times weekly.
- Cortisol and appetite effects. All three produce minimal cortisol elevation and no appetite stimulation.
- Regulatory status. Sermorelin was formerly FDA-approved as Geref (NDA 20-443), withdrawn in 2008; it remains legal with a prescription through US compounding pharmacies. Both CJC-1295 forms have no FDA approval history and faced compounding restrictions after the 2024 FDA review. All three are prohibited by WADA under Section S2.2.4.
- Primary use context. Sermorelin: anti-aging, GH deficiency, compounding prescriptions. CJC-1295 without DAC: research protocols and combination stacking. CJC-1295 with DAC: sustained GH elevation with less frequent dosing.